Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 2 | Journal for ImmunoTherapy of Cancer

Figure 2

From: A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma

Figure 2

Baseline and Peak ELISPOT results for 14 evaluable patients and median and mean CAP1-6D (Panel A) and wild-type (Panel B) T Cell response per dose level. Baseline (blue diamond) and peak (green triangle) T cell responses by ELISPOT for each of the 14 evaluable patients. Median and mean T cell response by ELISPOT (spots per 104 CD8+ cells) measured after at least 3 cycles is indicated by the orange bars per each arm. For CAP1-6D (Panel A) median/mean Arm A (0.01 mg) response = 10.5/36.5; median/mean Arm B (0.1 mg) response = 51.75/148.45; median/mean Arm C (1 mg) response = 270.63/247.69. P = 0.028 as measured by Mann–Whitney Rank Sum Test comparing medians. For wild-type (Panel B) median/mean Arm A (0.01 mg) response = 3/22.05; median/mean Arm B (0.1 mg) response = 81/120.5; median/mean Arm C (1 mg) response = 222.5/188.5. P = 0.028 as measured by Mann–Whitney Rank Sum Test comparing medians.

Back to article page